货号：DT2025060252
CAS：1304701-57-2
规格：mg(更多包装需求请咨询客服)
纯度：≥98%
生产商：试剂家

生物活性：Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment[1][2][3].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Edoxaban-d6 相关抗体:
PAR2 Antibody (YA2455)
Protein C Antibody (YA2461)
Thrombomodulin Antibody (YA891)
Thrombomodulin Antibody (YA892)
F2 Antibody
PAR6 Antibody (YA1536)
Prothrombin Antibody (YA1753)
PAR4 Antibody (YA2603)
Protein S Antibody (YA2919)
Antithrombin III Antibody (YA3352)
分子量：554.09
Formula：C24H24D6ClN7O4S
CAS 号：1304701-57-2
非标记 CAS：480449-70-5
性状：固体
颜色：White to off-white
中文名称：依度沙班-d6；伊多塞班-d6；艾多沙班-d6
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Powder：-20°C：3 years，4°C：2 years
In solvent：-80°C：6 months，-20°C：1 month
纯度 & 产品资料
纯度： ≥99.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.
 [Content Brief]
[3]. Mendell J, Lee F, Chen S, The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. J Cardiovasc Pharmacol. 2013 Apr 23. [Epub ahead of print]
 [Content Brief]
[4]. Stacy ZA, et al. Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Cardiol Ther. 2016 Jun;5(1):1-18.
 [Content Brief]